June 25, 2015 SHARE Email Facebook Twitter Human Services, National Issues, Statement Harrisburg, PA – Governor Tom Wolf today released the following statement in response to the Supreme Court’s ruling in King v. Burwell:“I am extremely pleased with the Supreme Court’s ruling in King v. Burwell. As a result of this decision, roughly 382,000 Pennsylvanians will keep their much-needed assistance to help them afford health care.“I took steps to protect Pennsylvania’s consumers by putting in place a contingency in the event the Supreme Court ruled people are not eligible for subsidies, but I am pleased to say that we will no longer need to rely on this plan.“My administration will be notifying the federal government that we will be withdrawing our plan to set up a state based health insurance marketplace in Pennsylvania.”MEDIA CONTACT: Jeff Sheridan – 717.783.1116 Governor Wolf Issues Statement On King v. Burwell Supreme Court Ruling; Says Administration Will Withdraw State Based Health Insurance Marketplace Plan
64 Views no discussions Share HealthInternationalLifestylePrint Asthma pill hailed in early test by: Associated Free Press – August 8, 2016 Share Share Sharing is caring! Tweet (File photo)PARIS, France (AFP) — The first new asthma pill in nearly 20 years has led to a sharp improvement in symptoms for chronic sufferers of the disease, according to an early test of the drug.A treatment called fevipiprant eased asthma symptoms, improved lung function, reduced inflammation and repaired the lining of airways, researchers reported on Friday.“This new drug could be a game-changer for future treatment of asthma,” said Chris Brightling, a professor at the University of Leicester, central England, who led the study.Asthma is a long-term disease in which the immune system in the airways goes into overdrive, and wheezing, coughing and restricted breathing are the result.People with chronic asthma can prevent or ease the symptoms by using an inhaler or steroids, but these can have hefty side effects.Fevipiprant seeks to prevent immune cells called eosinophils from moving into the bronchial walls, where they restrict and inflame the airways.In the trial reported in the British journal The Lancet Respiratory Medicine, researchers enrolled 61 asthmatics and divided them into two groups.One group was given 225mg of the drug twice a day for 12 weeks and the other participants were given a dummy lookalike pill, called a placebo.A key goal was to monitor levels of eosinophils in sputum — a long-used biomarker of asthma.People who do have not have asthma typically have an eosinophil count of less than one percent, while those with moderate-to-severe asthma have a reading of about five percent.Those who took the drug in the experiment and had moderate-to-severe asthma saw their average count of 5.4 percent fall to 1.1 percent over 12 weeks.No adverse effects were reported.Those who took the drug also reported extensive easing of symptoms, the team said.“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks,” Brightling said in a press release issued by the university.“This new treatment, fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms.”– Test hurdles –Bigger studies are needed before the prototype drug, made by Novartis, can be approved under the three-phase process to test a novel medicine for safety and effectiveness.“More research is needed and we’re a long way off seeing a pill for asthma being made available over the pharmacy counter,” Samantha Walker, director of research at the charity Asthma UK, said through Britain’s Science Media Centre.“But it’s an exciting development and one which, in the long term, could offer a real alternative to current treatments.”Novartis, on its website, says fevipiprant is now in Phase III testing, with a hoped-for date of 2019 for filing for a licence.Around 334 million people have asthma, a figure that inflicts a major burden on economies and health systems, according to a 2014 investigation, the Global Asthma Report.Fourteen percent of the world’s children experience asthma symptoms, it said — a trend that seems to have risen sharply in poor- and middle-income countries in the past couple of decades.Lifestyle and environmental influences, such as tobacco smoke, house dust mites, types of pollen and airborne particulate pollution, are known factors in asthma.But many aspects of the disease are unclear and vulnerability varies greatly according to the individual.
Spencer Haywood is the Curt Flood of basketball. When Curt Flood brought about free agency in baseball, he changed the game forever. Spencer Haywood did the same for pro basketball when he left college early. Even though he had to go to court to do so, he left the University of Detroit and was drafted in 1969 by the Buffalo Braves, an ABA team. In 1969-70 he was a member of the Denver Rockets. It was during this time that the NBA tried to keep him from playing. They went so far as to escort him off the floor in one game and in another game the other players boycotted.After all this turmoil, Haywood brought about the merger of the ABA and NBA. From that point in the early 70’s until today players may join the NBA at any point after high school. Haywood paved the way for players like Julius Irving, George Gervin, and Moses Malone. Before you think this is the only thing that made Haywood famous, you are totally wrong. In 14 years as a pro Haywood scored more than 17,000 points and was even the league’s MVP.